Myxedema coma
ICD-10 E03.5 is a billable code used to indicate a diagnosis of myxedema coma.
Myxedema coma is a severe and life-threatening form of hypothyroidism characterized by a significant decrease in thyroid hormone levels, leading to a state of extreme metabolic slowdown. It typically occurs in individuals with long-standing untreated hypothyroidism, often precipitated by factors such as infection, cold exposure, trauma, or the use of certain medications. Clinically, patients may present with profound lethargy, hypothermia, bradycardia, hypotension, and altered mental status, which can progress to coma. The condition is marked by the accumulation of mucopolysaccharides in the skin and other tissues, leading to the characteristic myxedematous appearance. Diagnosis is confirmed through thyroid function tests, which typically show low levels of free thyroxine (T4) and elevated thyroid-stimulating hormone (TSH). Immediate treatment involves intravenous administration of thyroid hormone replacement, along with supportive care to address any precipitating factors. Due to its critical nature, myxedema coma requires prompt recognition and intervention to prevent morbidity and mortality.
Thorough documentation of thyroid function tests, clinical symptoms, and treatment protocols.
Management of patients with chronic hypothyroidism presenting with acute decompensation.
Ensure clear documentation of the patient's history of thyroid disease and any recent changes in medication or health status.
Detailed notes on the patient's presentation, vital signs, and immediate interventions performed.
Patients presenting with altered mental status and hypothermia requiring rapid assessment and treatment.
Document all emergency interventions and the rationale for diagnosis to support coding.
Used to confirm diagnosis in patients suspected of myxedema coma.
Document the rationale for testing and results.
Endocrinologists should ensure comprehensive lab results are included in the patient's record.
Common symptoms include severe lethargy, hypothermia, bradycardia, hypotension, and altered mental status. Patients may also exhibit dry skin and swelling.
